Literature DB >> 2190436

[The treatment of ankylosing spondylitis with auranofin (Ridaura)].

K Grasedyck1, M Schattenkirchner, K Bandilla.   

Abstract

Auranofin has no influence on axial skeleton manifestation of ankylosing spondylitis, neither on clinical complaints, nor on function and inflammatory parameters. Peripheral arthritis is possibly influenced positively, but this cannot be stated definitely because of the low number of cases in this study. This question must be analyzed in larger collectives, as alternatives to conventional therapy are needed for the treatment of peripheral joint involvement of ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190436

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  5 in total

Review 1.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

2.  Assessment and treatment of psoriatic spondylitis.

Authors:  Peter Nash
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 3.  Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.

Authors:  E S Strobel; E Fritschka
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 4.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

5.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.